title: An anatomical basis for opponent process mechanisms of opiate withdrawal.
abstract: Opponent process theory predicts that the first step in the induction of drug withdrawal is the activation of reward-related circuitry. Using the acoustic startle reflex as a model of anxiety-like behavior in rats, we show the emergence of a negative affective state during withdrawal after direct infusion of morphine into the ventral tegmental area (VTA), the origin of the mesolimbic dopamine system. Potentiation of startle during withdrawal from systemic morphine exposure requires a decrease in opiate receptor stimulation in the VTA and can be relieved by administration of the dopamine receptor agonist apomorphine. Together, our results suggest that the emergence of anxiety during withdrawal from acute opiate exposure begins with activation of VTA mesolimbic dopamine circuitry, providing a mechanism for the opponent process view of withdrawal.
authors: Graduate Program in Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, USA.
authors: Anna K
authors: AK
authors: Radke
authors: Patrick E
authors: PE
authors: Rothwell
authors: Jonathan C
authors: JC
authors: Gewirtz
references: J Neurosci. 2006 May 24;26(21):5720-6
references: 16723528
references: Neuropsychopharmacology. 2008 Nov;33(12):3010-20
references: 18256592
references: Neuropsychopharmacology. 2010 Jan;35(1):105-35
references: 19693004
references: Psychol Rev. 2004 Jan;111(1):33-51
references: 14756584
references: Mol Pharmacol. 2008 Nov;74(5):1463-75
references: 18703671
references: J Pharmacol Exp Ther. 1995 Feb;272(2):781-5
references: 7853194
references: J Neurosci. 2005 May 11;25(19):4725-32
references: 15888648
references: Science. 1984 May 4;224(4648):516-7
references: 6324347
references: Prog Neurobiol. 2004 Dec;74(5):301-20
references: 15582224
references: Annu Rev Psychol. 2003;54:25-53
references: 12185211
references: Life Sci. 1982 Jun 21;30(25):2207-14
references: 6180276
references: Behav Brain Res. 2002 Feb 1;129(1-2):17-29
references: 11809491
references: Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50
references: 1347943
references: J Pharmacol Exp Ther. 2003 Feb;304(2):603-9
references: 12538812
references: Neuropsychopharmacology. 2009 Sep;34(10):2285-95
references: 19494807
references: Neuroscience. 1999;94(4):1125-32
references: 10625052
references: J Neurosci. 1999 Dec 15;19(24):11027-39
references: 10594083
references: Brain Res. 1987 Jan 6;400(2):205-18
references: 2880637
references: J Neurosci. 2008 Nov 26;28(48):12682-90
references: 19036961
references: Biol Psychiatry. 2006 Jun 15;59(12):1151-9
references: 16566899
references: J Neurosci. 2008 Dec 17;28(51):13856-65
references: 19091975
references: J Comp Neurol. 1978 Aug 1;180(3):509-32
references: 659673
references: J Comp Neurol. 2002 Dec 2;454(1):15-33
references: 12410615
references: Science. 1988 Nov 4;242(4879):715-23
references: 2903550
references: Pharmacol Biochem Behav. 1994 May;48(1):1-8
references: 8029278
references: Eur J Neurosci. 2009 May;29(10):2029-34
references: 19453632
references: Neuroscience. 1990;37(3):767-73
references: 2247222
references: Pharmacol Biochem Behav. 1984 Jun;20(6):925-34
references: 6463076
references: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):334-44
references: 19150477
references: Neuroscience. 2006;139(4):1201-10
references: 16600512
references: Brain Res. 1982 Apr 22;238(1):266-71
references: 7083021
references: Eur J Pharmacol. 1992 Oct 20;221(2-3):227-34
references: 1426002
references: J Neurosci. 1995 Sep;15(9):5859-69
references: 7666171
references: Pharmacol Biochem Behav. 1991 Jun;39(2):469-72
references: 1946587
references: Psychopharmacology (Berl). 1995 Jan;117(1):102-9
references: 7724693
references: Nature. 1994 Sep 8;371(6493):155-7
references: 7915401
references: Neuropsychopharmacology. 2010 Dec;35(13):2579-89
references: 20811341
references: Behav Neurosci. 1995 Feb;109(1):91-105
references: 7734084
references: J Neurosci. 2007 May 23;27(21):5730-43
references: 17522317
references: Psychopharmacology (Berl). 2004 Jan;171(2):140-7
references: 13680079
references: J Neurosci. 2006 Jun 14;26(24):6450-7
references: 16775132
references: Behav Neurosci. 1997 Dec;111(6):1324-34
references: 9438801
references: J Pharmacol Exp Ther. 1992 May;261(2):669-77
references: 1578378
references: Eur J Neurosci. 1999 Mar;11(3):1037-41
references: 10103095
references: Psychol Rev. 1974 Mar;81(2):119-45
references: 4817611
references: J Neurosci. 2006 Apr 5;26(14):3855-63
references: 16597740
references: Brain Res. 2002 Aug 2;945(2):151-9
references: 12126877
references: Psychopharmacology (Berl). 2006 Aug;187(2):143-53
references: 16724186
references: Synapse. 1995 Oct;21(2):140-8
references: 8584975
references: Pharmacol Biochem Behav. 1999 Sep;64(1):123-30
references: 10495006
references: Neuroscience. 2005;134(1):9-19
references: 15939543
references: Pharmacol Biochem Behav. 1979 Sep;11(3):289-95
references: 504308
references: Science. 1997 Oct 3;278(5335):52-8
references: 9311926
references: Trends Neurosci. 1992 May;15(5):186-91
references: 1377426
references: Ann N Y Acad Sci. 1999 Jun 29;877:1-32
references: 10415640
references: Neuropsychopharmacology. 2003 Jun;28(6):1140-9
references: 12700697
references: J Neurosci. 2000 Oct 15;20(20):RC102
references: 11027253
references: Brain Struct Funct. 2008 Sep;213(1-2):43-61
references: 18651175
references: Eur J Neurosci. 2002 Oct;16(7):1377-89
references: 12405997
references: Behav Neurosci. 2003 Oct;117(5):995-1005
references: 14570549
references: J Neurochem. 1992 May;58(5):1620-5
references: 1313849
references: J Neurosci. 1992 Feb;12(2):483-8
references: 1346804
references: Eur J Neurosci. 2007 Jun;25(12):3713-8
references: 17610590